Targeted therapy using polymyxin B hemadsorption in patients with sepsis: a post-hoc analysis of the JSEPTIC-DIC study and the EUPHRATES trial.
Endotoxemia
Endotoxin
Hemadsorption
Polymyxin B
Sepsis
Journal
Critical care (London, England)
ISSN: 1466-609X
Titre abrégé: Crit Care
Pays: England
ID NLM: 9801902
Informations de publication
Date de publication:
21 06 2023
21 06 2023
Historique:
received:
30
03
2023
accepted:
15
06
2023
medline:
23
6
2023
pubmed:
22
6
2023
entrez:
21
6
2023
Statut:
epublish
Résumé
Polymyxin B hemadsorption (PMX-HA) reduces blood endotoxin levels, but characteristics of patients with sepsis likely to benefit from PMX-HA are not well known. We sought to identify patient subgroups likely to benefit from PMX-HA. We retrospectively identified 1911 patients with sepsis from a retrospective observational study in Japan (the JSEPTIC-DIC study) and 286 patients with endotoxemic septic shock from a randomized controlled trial in North America that restricted patients to those with high endotoxin activity (the EUPHRATES trial). We applied the machine learning-based causal forest model to the JSEPTIC-DIC cohort to investigate heterogeneity in treatment effects of PMX-HA on 28-day survival after adjusting for potential confounders and ascertain the best criteria for PMX-HA use. The derived criteria for targeted therapy by PMX-HA were validated using the EUPHRATES trial cohort. The causal forest model revealed heterogeneity in treatment effects of PMX-HA. Since patients having higher treatment effects were more likely to have severe coagulopathy and hyperlactatemia, we identified the potential treatment targets of PMX-HA as patients with PT-INR > 1.4 or lactate > 3 mmol/L. In the EUPHRATES trial cohort, PMX-HA use on the targeted subpopulation (75% of all patients) was significantly associated with higher 28-day survival (PMX-HA vs. control, 68% vs. 52%; treatment effect of PMX-HA, + 16% [95% CI + 2.2% to + 30%], p = 0.02). Abnormal coagulation and hyperlactatemia in septic patients with high endotoxin activity appear to be helpful to identify patients who may benefit most from PMX-HA. Our findings will inform enrollment criteria for future interventional trials targeting patients with coagulopathy and hyperlactatemia.
Sections du résumé
BACKGROUND
Polymyxin B hemadsorption (PMX-HA) reduces blood endotoxin levels, but characteristics of patients with sepsis likely to benefit from PMX-HA are not well known. We sought to identify patient subgroups likely to benefit from PMX-HA.
METHODS
We retrospectively identified 1911 patients with sepsis from a retrospective observational study in Japan (the JSEPTIC-DIC study) and 286 patients with endotoxemic septic shock from a randomized controlled trial in North America that restricted patients to those with high endotoxin activity (the EUPHRATES trial). We applied the machine learning-based causal forest model to the JSEPTIC-DIC cohort to investigate heterogeneity in treatment effects of PMX-HA on 28-day survival after adjusting for potential confounders and ascertain the best criteria for PMX-HA use. The derived criteria for targeted therapy by PMX-HA were validated using the EUPHRATES trial cohort.
RESULTS
The causal forest model revealed heterogeneity in treatment effects of PMX-HA. Since patients having higher treatment effects were more likely to have severe coagulopathy and hyperlactatemia, we identified the potential treatment targets of PMX-HA as patients with PT-INR > 1.4 or lactate > 3 mmol/L. In the EUPHRATES trial cohort, PMX-HA use on the targeted subpopulation (75% of all patients) was significantly associated with higher 28-day survival (PMX-HA vs. control, 68% vs. 52%; treatment effect of PMX-HA, + 16% [95% CI + 2.2% to + 30%], p = 0.02).
CONCLUSIONS
Abnormal coagulation and hyperlactatemia in septic patients with high endotoxin activity appear to be helpful to identify patients who may benefit most from PMX-HA. Our findings will inform enrollment criteria for future interventional trials targeting patients with coagulopathy and hyperlactatemia.
Identifiants
pubmed: 37344804
doi: 10.1186/s13054-023-04533-3
pii: 10.1186/s13054-023-04533-3
pmc: PMC10286480
doi:
Substances chimiques
Polymyxin B
J2VZ07J96K
Anti-Bacterial Agents
0
Endotoxins
0
Types de publication
Randomized Controlled Trial
Observational Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
245Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
© 2023. The Author(s).
Références
Crit Care Med. 2014 May;42(5):1187-93
pubmed: 24365858
Am J Epidemiol. 2014 Mar 15;179(6):764-74
pubmed: 24589914
Crit Care Med. 2021 Nov 1;49(11):e1063-e1143
pubmed: 34605781
JAMA. 2018 Oct 9;320(14):1455-1463
pubmed: 30304428
JAMA. 2019 May 28;321(20):2003-2017
pubmed: 31104070
Intensive Care Med. 2021 Nov;47(11):1181-1247
pubmed: 34599691
Ann Intensive Care. 2021 Sep 26;11(1):141
pubmed: 34568980
Innate Immun. 2014 Nov;20(8):881-7
pubmed: 24398861
Immunity. 2019 Dec 17;51(6):983-996.e6
pubmed: 31836429
Intensive Care Med. 2015 Jun;41(6):975-84
pubmed: 25862039
Crit Care. 2014 Jun 09;18(3):309
pubmed: 25043934
Sci Data. 2018 Dec 11;5:180243
pubmed: 30531950
JAMA. 2016 Feb 23;315(8):801-10
pubmed: 26903338
Nephron. 2023;147(1):17-20
pubmed: 35790144
Crit Care Med. 2003 Apr;31(4):1250-6
pubmed: 12682500
Shock. 2005 May;23(5):400-5
pubmed: 15834304
J Infect Dis. 2004 Aug 1;190(3):527-34
pubmed: 15243928
Proc Natl Acad Sci U S A. 2016 Jul 5;113(27):7353-60
pubmed: 27382149
Circulation. 2023 Jan 10;147(2):132-141
pubmed: 36314118
Int J Environ Res Public Health. 2021 Feb 02;18(3):
pubmed: 33540610
JAMA. 2009 Jun 17;301(23):2445-52
pubmed: 19531784
Crit Care. 2017 Jun 7;21(1):134
pubmed: 28592318
Blood Purif. 2017;44(3):193-197
pubmed: 28601867
Intensive Care Med. 2018 Dec;44(12):2205-2212
pubmed: 30470853